Laboratory Studies
- DNA diagnosis is now available, and documentation of the IKBKAP mutation is the criterion standard to confirm the diagnosis. However, in a patient in whom this diagnosis is suspected, a tentative diagnosis can be made using a constellation of clinical criteria. Traditionally, 5 cardinal criteria should be present for a firm diagnosis.
- Parents of Ashkenazi Jewish ancestry: Both parents should have a history of being of Eastern European extraction.
- Absence of fungiform papillae on the tongue: The highly vascularized fungiform papillae on the anterior third of the tongue are absent resulting in a smooth and glistening tongue tip. See following image.
Absence of fungiform papillae on the tongue. The highly vascularized fungiform papillae on the anterior third of the tongue are absent resulting in a smooth and glistening tongue tip. - Decreased deep tendon reflexes: In 95% of patients with familial dysautonomia (FD), knee jerks cannot be elicited.
- Lack of axon flare following intradermal histamine: Histamine phosphate in a 1:10,000 dilution injected intradermally does not produce pain or an axon flare. See following image.
Lack of axon flare following intradermal histamine. Histamine phosphate in a 1:10,000 dilution injected intradermally does not produce pain or an axon flare. - No overflow tears with emotional crying: Normally overflow emotional tearing can be delayed until age 7 months, but Schirmer tear testing usually shows diminished baseline tear flow.
Axelrod FB. Familial dysautonomia. Muscle Nerve. Mar 2004;29(3):352-63. [Medline].
Axelrod FB. A world without pain or tears. Clin Auton Res. Apr 2006;16(2):90-7. [Medline].
Riley CM, Day RL, Greeley DM. Central autonomic dysfunction with defective lacrimation: report of five cases. In: Pediatrics. Vol. 3. 1949:468-77.
Anderson SL, Coli R, Daly IW, et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet. Mar 2001;68(3):753-8. [Medline].
Leyne M, Mull J, Gill SP, et al. Identification of the first non-Jewish mutation in familial Dysautonomia. Am J Med Genet A. May 1 2003;118A(4):305-8. [Medline].
Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet. Mar 2001;68(3):598-605. [Medline].
Pearson J, Pytel BA, Grover-Johnson N, et al. Quantitative studies of dorsal root ganglia and neuropathologic observations on spinal cords in familial dysautonomia. J Neurol Sci. Jan 1978;35(1):77-92. [Medline].
Axelrod FB, Goldberg JD, Ye XY, et al. Survival in familial dysautonomia: Impact of early intervention. J Pediatr. Oct 2002;141(4):518-23. [Medline].
Brunt PW, McKusick VA. Familial dysautonomia. A report of genetic and clinical studies, with a review of the literature. Medicine (Baltimore). Sep 1970;49(5):343-74. [Medline].
Porges RF, Axelrod FB, Richards M. Pregnancy in familial dysautonomia. Am J Obstet Gynecol. Nov 1 1978;132(5):485-8. [Medline].
Elkayam L, Matalon A, Tseng CH, et al. Prevalence and severity of renal disease in familial dysautonomia. Am J Kidney Dis. Nov 2006;48(5):780-6. [Medline].
Clayson D, Welton W, Axelrod FB. Personality development and familial dysautonomia. Pediatrics. Feb 1980;65(2):269-74. [Medline].
Sands SA, Giarraffa P, Jacobson CM, et al. Familial dysautonomia's impact on quality of life in childhood, adolescence, and adulthood. Acta Paediatr. Apr 2006;95(4):457-62. [Medline].
Welton W, Clayson D, Axelrod FB, et al. Intellectual development and familial dysautonomia. Pediatrics. May 1979;63(5):708-12. [Medline].
Axelrod FB, Iyer K, Fish I, et al. Progressive sensory loss in familial dysautonomia. Pediatrics. Apr 1981;67(4):517-22. [Medline].
Blumenfeld A, Slaugenhaupt SA, Axelrod FB, et al. Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nat Genet. Jun 1993;4(2):160-4. [Medline].
Axelrod FB, Liebes L, Gold-Von Simson G, Mendoza S, Mull J, Leyne M, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. Nov 2011;70(5):480-3. [Medline]. [Full Text].
Cohen-Kupiec R, Pasmanik-Chor M, Oron-Karni V, Weil M. Effects of IKAP/hELP1 deficiency on gene expression in differentiating neuroblastoma cells: implications for familial dysautonomia. PLoS One. Apr 29 2011;6(4):e19147. [Medline]. [Full Text].
Axelrod FB, Goldstein DS, Holmes C, et al. Pattern of plasma levels of catecholamines in familial dysautonomia. Clin Auton Res. Aug 1996;6(4):205-9. [Medline].
Axelrod FB, Goldberg JD, Rolnitzky L, et al. Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res. Aug 2005;15(4):284-91. [Medline].
Diamond GA, D'Amico RA, Axelrod FB. Optic nerve dysfunction in familial dysautonomia. Am J Ophthalmol. Dec 15 1987;104(6):645-8. [Medline].
Mendoza-Santiesteban CE, Hedges TR 3rd, Norcliffe-Kaufmann L, Warren F, Reddy S, Axelrod FB, et al. Clinical Neuro-ophthalmic Findings in Familial Dysautonomia. J Neuroophthalmol. Sep 13 2011;[Medline].
Bernardi L, Hilz M, Stemper B, et al. Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. Am J Respir Crit Care Med. Jan 15 2003;167(2):141-9. [Medline].
Maayan C, Carley DW, Axelrod FB, et al. Respiratory system stability and abnormal carbon dioxide homeostasis. J Appl Physiol. Mar 1992;72(3):1186-93. [Medline].
Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. Feb 2004;137(2):337-42. [Medline].
Anderson SL, Qiu J, Rubin BY. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun. Jun 20 2003;306(1):303-9. [Medline].
Ilsar M, Hartstein ME, Maayan C. Punctal occlusion in patients with familial dysautonomia. Ann Ophthalmology. 1998;30(6):375-378.
Gungor I, Schor K, Rosenthal P, et al. The Boston Scleral Lens in the treatment of pediatric patients. J AAPOS. Jun 2008;12(3):263-7. [Medline].
Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. Jul 2000;107(7):1347-51; discussion 1351-2. [Medline].
Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. Jun 2004;111(6):1115-20. [Medline].
Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. Aug 2000;84(8):826-33. [Medline]. [Full Text].
Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work?. Ocul Surf. Jul 2004;2(3):177-87. [Medline].
Ghinelli E. The Riley-Day syndrome. Arch Ophthalmol. Dec 1968;80(6):732-43.
Dohlman C, Waller S, Netland P. Keratoprosthesis Surgery. In: Lindquist T, Lindstrom R, eds. Ophthalmic Surgery. Vol L. 1996:1-32.
Ngai J, Kreynin I, Kim JT, et al. Anesthesia management of familial dysautonomia. Paediatr Anaesth. Jun 2006;16(6):611-20. [Medline].
AMX: Extract of human amniotic membrane. Presented at Italian Ocular Surface Society, Venice, Italy, June 2005.
Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. Feb 2002;86(2):181-4. [Medline].
Axelrod FB. Familial dysautonomia. In: Burg FD, Ingelfinger JR, Polin RA, eds. Current Pediatric Therapy. 15th ed. Philadelphia, Pa: WB Saunders Co; 1996:91-94.
Axelrod FB. Familial dysautonomia: a review of the current pharmacological treatments. Expert Opin Pharmacother. Apr 2005;6(4):561-7. [Medline].
Cappellari M, Cavallaro T, Ferrarini M, Cabrini I, Taioli F, Ferrari S, et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst. Jun 2011;16(2):119-29. [Medline].
Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. Feb 2005;139(2):242-6. [Medline].

